We are live on ! Find out more
AMBI

Ambit Biosciences Corp
AMBI

Delisted

AMBI was delisted on the 10th of November, 2014.

Back to rankings

36 hedge funds and large institutions have $67M invested in Ambit Biosciences Corp in 2014 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

15% less capital invested

Capital invested by funds: $78.8M → $67M (-$11.8M)

22% less funds holding

Funds holding: 46 → 36 (-10)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

63% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 16

Holders
36
Holders Change
-10
Holders Change %
-21.74%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
6
Increased
12
Reduced
9
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aisling Capital
New York
+$11.6M
2
GCM
Gruss Capital Management
New York
+$2.51M
3
GPP
Great Point Partners
Connecticut
+$2.35M
4
SFM
Sphera Funds Management
Israel
+$905K
5
B
Bailard
California
+$407K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.65M
2
RG
Redmile Group
California
-$3.35M
3
WC
Wexford Capital
Florida
-$1.57M
4
Morgan Stanley
Morgan Stanley
New York
-$751K
5
CA
Commerzbank Aktiengesellschaft
Germany
-$648K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management I
California
$14.4M – – –
AC
2
Aisling Capital
New York
$11.4M +$11.6M +1,650,156 New
O
3
OrbiMed
New York
$10.3M – – –
GPP
4
Great Point Partners
Connecticut
$7.28M +$2.35M +334,634 +47%
BBA
5
Baker Bros. Advisors
New York
$5.17M – – –
Fidelity Investments
6
Fidelity Investments
Massachusetts
$2.75M -$3.65M -520,005 -57%
GCM
7
Gruss Capital Management
New York
$2.47M +$2.51M +357,492 New
WC
8
Wexford Capital
Florida
$2.28M -$1.57M -224,383 -41%
SFM
9
Sphera Funds Management
Israel
$1.92M +$905K +129,100 +87%
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.76M +$299K +42,655 +20%
AG
11
Artal Group
Luxembourg
$1.73M – – –
EAM
12
Eventide Asset Management
Massachusetts
$1.04M +$140K +20,000 +15%
BIT
13
BlackRock Institutional Trust
California
$689K +$46.7K +6,663 +7%
B
14
Bailard
California
$643K +$407K +58,000 +166%
Macquarie Group
15
Macquarie Group
Australia
$529K – – –
BA
16
BlackRock Advisors
Delaware
$376K +$32.3K +4,610 +9%
BCM
17
Bridgeway Capital Management
Texas
$312K – – –
DCM
18
Driehaus Capital Management
Illinois
$276K -$124K -17,708 -31%
NI
19
Numeric Investors
Massachusetts
$243K -$164K -23,353 -40%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$242K -$428 -61 -0.2%
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$239K +$243K +34,600 New
BFA
22
BlackRock Fund Advisors
California
$187K +$5.44K +776 +3%
RIL
23
Rothschild Investment LLC
Illinois
$182K – – –
Bank of New York Mellon
24
Bank of New York Mellon
New York
$166K +$877 +125 +0.5%
Two Sigma Investments
25
Two Sigma Investments
New York
$150K +$32.1K +4,573 +27%
1
2 3

AMBI Hedge Fund Activity: Q2 2014 in Review

36 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q2 2014, worth a combined $67M — down 15% from $78.8M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AMBI and 6 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 12 added.

The largest buyer was Aisling Capital, opening a new position worth an estimated $11.6M. The largest seller was Fidelity Investments, cutting an estimated $3.65M.

  • 36 institutional investors held Ambit Biosciences Corp (AMBI) as of Q2 2014, down from 46 in Q1 2014.
  • Funds reported $67M of Ambit Biosciences Corp stock for Q2 2014, down 15% quarter-over-quarter.
  • 6 funds opened new Ambit Biosciences Corp positions in Q2 2014 and 16 closed out, a net change of -10 holders.
  • The largest Ambit Biosciences Corp buyer in Q2 2014 was Aisling Capital, an estimated $11.6M added.
  • The largest Ambit Biosciences Corp seller in Q2 2014 was Fidelity Investments, an estimated $3.65M sold.

Based on aggregated 13F filings for Q2 2014.